Genscript Biotech Corporation (HKG:1548) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$24.74
It's been a pretty great week for Genscript Biotech Corporation (HKG:1548) shareholders, with its shares surging 15% to HK$28.26 in the week since its latest half-year results. The results were positive, with revenue coming in at US$404m, beating analyst expectations by 5.3%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Genscript Biotech after the latest results.
Following the latest results, Genscript Biotech's seven analysts are now forecasting revenues of US$879.6m in 2026. This would be an okay 4.1% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with Genscript Biotech forecast to report a statutory profit of US$0.02 per share. In the lead-up to this report, the analysts had been modelling revenues of US$827.1m and earnings per share (EPS) of US$0.038 in 2026. So it's pretty clear the analysts have mixed opinions on Genscript Biotech after the latest results; even though they upped their revenue numbers, it came at the cost of a pretty serious reduction to per-share earnings expectations.
See our latest analysis for Genscript Biotech
The analysts also upgraded Genscript Biotech's price target 49% to HK$24.74, implying that the higher revenue expected to generate enough value to offset the forecast decline in earnings. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Genscript Biotech at HK$36.06 per share, while the most bearish prices it at HK$15.51. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that Genscript Biotech's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 8.4% growth on an annualised basis. This is compared to a historical growth rate of 12% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 18% annually. Factoring in the forecast slowdown in growth, it seems obvious that Genscript Biotech is also expected to grow slower than other industry participants.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Genscript Biotech. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Genscript Biotech going out to 2028, and you can see them free on our platform here..
Even so, be aware that Genscript Biotech is showing 2 warning signs in our investment analysis , you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.